<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02447796</url>
  </required_header>
  <id_info>
    <org_study_id>KA 15/60</org_study_id>
    <nct_id>NCT02447796</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine and Propofol As Sole Sedative Agent for Patients Undergoing Arteriovenous Fistula Surgery</brief_title>
  <official_title>A Comparative Study of Dexmedetomidine and Propofol As Sole Sedative Agent for Patients With End-Stage Renal Disease Undergoing Arteriovenous Fistula Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baskent University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baskent University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators designed a prospective randomized study to compare the conventionally used
      sedative drug propofol with a latest alternative dexmedetomidine (DEX), in patients with
      end-stage renal disease undergoing arteriovenous fistula (AVF) surgery.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of adverse effects such as respiratory and hemodynamic events</measure>
    <time_frame>up to 24 hours postoperative</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The sedation onset time with using BIS and recovery times during the procedure.</measure>
    <time_frame>up to 24 hours postoperative</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Arteriovenous Fistula</condition>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Propofol was administered at 1 mg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 mg/kg/h until the the begining of skin suture (n=24)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine (DEX)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DEX was administered at 1 μg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 μg/kg/h until the begining of skin suture (n=24)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Propofol was administered at 1 mg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 mg/kg/h until the the begining of skin suture (n=24).</description>
    <arm_group_label>Propofol</arm_group_label>
    <other_name>Pofol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>DEX was administered at 1 μg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 μg/kg/h until the begining of skin suture (n=24).</description>
    <arm_group_label>Dexmedetomidine (DEX)</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inclusion criteria were patients undergoing arteriovenous fistula (AVF) surgery aged
             between 20-70 with end stage renal failure on dialysis treatment.

        Exclusion Criteria:

          -  Exclusion criteria were decompensated respiratory or heart failure, liver failure,
             obesity (body mass index&gt;30), severe obstructive sleep apnea, need for additional
             different drugs for sedation, chronic use of alcohol, opioids or other sedative
             drugs,mental disorders, cognitive disorders, language problems and history of allergy
             to any medications used in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anis Aribogan, Prof md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baskent University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ozlem Ozmete, MD</last_name>
    <phone>+903223272727</phone>
    <phone_ext>2461</phone_ext>
    <email>ozlemyilma@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cagla Bali, MD</last_name>
    <phone>+905320613026</phone>
    <email>caglaetike@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Baskent University School of Medicine Adana Research and Teaching Center</name>
      <address>
        <city>Adana</city>
        <zip>01250</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ozlem Ozmete, MD</last_name>
      <phone>+903223272727</phone>
      <email>ozlemyilma@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2015</study_first_submitted>
  <study_first_submitted_qc>May 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2015</study_first_posted>
  <last_update_submitted>May 18, 2015</last_update_submitted>
  <last_update_submitted_qc>May 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baskent University</investigator_affiliation>
    <investigator_full_name>Ozlem Ozmete</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>(AVF)</keyword>
  <keyword>surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fistula</mesh_term>
    <mesh_term>Arteriovenous Fistula</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Hypnotics and Sedatives</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

